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Abstract The principles of establishing biosimilarity are
to demonstrate structural and functional similarity to a
reference product using the most discriminatory analytical
methods. There is still considerable controversy on the
scientific basis for extrapolation of indications for
biosimilars, which has been strengthened by diverging
global regulatory decision making. Closely related to the
question of extrapolation is the question of how to com-
municate the evidence base for authorizing biosimilars to
healthcare professionals. In this paper we will consider
some of the discussions around extrapolation of indications
and the implications of decisions of various regulatory
agencies in the world regarding the authorization and
labeling of biosimilars.
Key Points
There are considerable differences in regulatory
decision making in terms of extrapolation of
indications.
Currently available data do not suggest any concerns
on extrapolating immunogenicity across indications.
Opportunities for savings exist with advanced new
treatments and improved disease management.
1 Introduction
Biosimilar regulatory pathways have been established
around the world to provide an abbreviated route for copy
versions of biologicals, so-called biosimilars. The aim of the
procedure is to demonstrate physico-chemical and func-
tional similarity to an already authorized reference product,
to an adequately rigorous level, that enables comparative
clinical studies to focus on evaluating the impact of any
detected differences using the most sensitive clinical
parameters—rather than to demonstrate overall clinical
benefit versus risk per se. If this is done successfully, a
product is termed biosimilar and can rely on the clinical
experience obtained with its reference product. Extrapola-
tion is the foundation of the biosimilar regulatory framework
and is here defined as granting regulatory approval for
indications of the referencemedicine that are not specifically
studied during the clinical development of the biosimilar
medicine [1]. This tailored regulatory package allows
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To date, 13 distinct biosimilar drug substances (repre-
senting six different molecules) have received marketing
approval in the EU and an increasing number is in devel-
opment. The majority of the first approved biosimilars
concerned recombinant homologs of naturally occurring
proteins (i.e., somatropin, epoetin, filgrastim, follitropin,
and insulin glargine). The next wave of biosimilars will
largely consist of monoclonal antibodies, which are mainly
used in the oncology and immunology setting [2]. These
products are more complex structurally, but also pose
considerable challenges to investigate clinically, particu-
larly in the oncology setting [3]. In 2013, the first
biosimilar monoclonal antibody obtained marketing
authorization in the EU, CT-P13, which is a biosimilar
version of the tumor necrosis factor a (TNFa)-targeting
monoclonal antibody infliximab and is sold under the brand
names Inflectra (Hospira) and Remsima (Celltrion/Orion
Pharma). Several other products are currently under review
at regulatory agencies.
Muchdebate has centeredonwhichdata is required togrant
an approval for all indications of the product that is already
authorized on themarket, the reference product [4, 5]. Despite
this practice being well established in relation to the imple-
mentation of manufacturing changes for innovator products,
there is still controversy on the scientific basis for extrapola-
tion of indications for biosimilars [6, 7]. Should the applicant
provide comparative clinical data for all authorized indica-
tions of the original product, or can all indications be granted
using comparative clinical data in a subset of approved indi-
cations and the others granted through extrapolation based on
scientific grounds; and is clinical data always required to
obtain a marketing authorization as a biosimilar? Various
learned societies have taken the position that extrapolation of
indications should never be allowed and that clinical data
should be required for all indications [8–10]—a view that
would effectively raise the regulatory standards for biosimi-
lars above those applied for approval of major manufacturing
changes for innovator products.Closely related to the question
of extrapolation is the question of how to communicate the
evidence base for authorizing biosimilars to healthcare pro-
fessionals. Here we will consider some implications of deci-
sions of various regulatory agencies in theworld regarding the
extrapolation and labeling of biosimilars.
2 Extrapolation Controversies
In all regulatory regions that have adopted biosimilar reg-
ulations, including the WHO guidelines on evaluation of
similar biotherapeutic products, extrapolation is possible
depending on the overall evidence of similarity provided
from the comparability exercise and with adequate scien-
tific justification [11]. Extrapolation should take into
account the shared mechanism(s) of action in the requested
indications and the nature of the potential risks in the dif-
ferent patient populations. For the first biosimilars,
extrapolation was relatively straightforward, as the phar-
macological actions in the different indications are mostly
mediated via the same receptors. Epoetin, for example, is a
recombinant version of an endogenous hormone that
increases red blood cells through the promotion, survival,
proliferation, and differentiation of erythrocytic progeni-
tors [12]. Epoetin has multiple indications, but is mainly
prescribed in patients with anemia resulting from chronic
kidney disease (CKD) and to prevent transfusions in
chemotherapy-induced anemia. There is only one known
erythropoietin receptor and the mechanism of action is thus
considered to be the same for both indications. However,
patients with CKD are more responsive to epoetin and
lower doses are required for a therapeutic response. Fur-
thermore, a key safety concern for epoetin, the occurrence
of anti-drug antibodies resulting in pure red cell aplasia,
has only been reported in CKD patients and not in patients
receiving epoetin for chemotherapy-induced anemia. Thus,
providing pivotal clinical data in CKD allows the autho-
rization of biosimilar epoetins in chemotherapy-induced
anemia. Of note, for biosimilar epoetins currently autho-
rized in the EU, pivotal data in CKD was accompanied by
uncontrolled supportive data in the oncology setting.
For monoclonal antibodies, extrapolation is more com-
plex as their mechanism of action may depend on multiple
sites of the molecule. Furthermore, often no direct phar-
macodynamic marker exists for their activity, which means
that clinical studies are designed around (insensitive)
clinical end points, which makes it particularly challenging
to study these products in some oncology settings. How the
different structure–activity relationships of antibodies
contribute to efficacy and safety in the different indications
is often not fully understood. This incomplete knowledge
has been the basis for a controversy surrounding the
biosimilar infliximab CT-P13. In July 2014, following a
positive opinion of the Committee for Medicinal Products
for Human Use (CHMP), the European Commission
granted a marketing authorization to CT-P13 and granted
all indications for which Remicade was approved based
on three clinical studies that included rheumatoid arthritis
(RA) patients and ankylosing spondylitis (AS) patients.
Health Canada also approved CT-P13, but stated that
‘‘extrapolation to indications and uses pertaining to
Crohn’s disease (CD) and ulcerative colitis (UC) could not
be recommended due to differences between CT-P13 and
the reference product, that could have an impact on the
clinical safety and efficacy of these products in these
indications’’ [13]. In other regulatory regions, CT-P13 has
not received marketing authorization for the pediatric UC
and CD indications [14].
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The scientific basis for the differing views between EMA
and Health Canada apparently lies in observed differences
between CT-P13 and Remicade in afucosylated glycans,
which was associated with detectable differences in the
binding affinity of the therapeutic monoclonal antibody to
the FccRIIIa and FccRIIIb receptors as determined by sur-
face plasmon resonance. The observed difference in
FccRIIIb affinity did not lead to measurable differences in
binding to neutrophils and was not considered further.
FccRIIIa is involved in antibody-dependent cellular cyto-
toxicity (ADCC). In the majority of directly comparative
in vitro ADCC assays performed, there was no
detectable difference between CT-P13 and Remicade. In
contrast, a difference in ADCC was detected using a sen-
sitive enriched natural killer (NK) cell assay, from cells
isolated from donors and CD patients, in combination with a
target cell line that expresses supra-physiological levels of
the target antigen, tmTNFa. The applicant investigated this
further and found that these differences were not observed in
assays using whole blood, peripheral blood mononuclear
cells, or neutrophils as effector cells. The FccRIIIa receptor
exists as three polymorphic variants V/V, V/F, and F/F and
significant differences were observed in the V/V and V/F,
but not the F/F subgroup. The experiments were also per-
formed with added (diluted) serum from patients to mimic
the biological situation. In the presence of serum, the earlier
observed differences were no longer observed, consistent
with the results from other studies using more ‘physiologi-
cal’ assay conditions [15]. The EMA considered the
observed difference in a single, highly sensitive NK assay
not to be representative of the physiological situation. Based
on the same data, Health Canada concluded that, because
ADCC may be an active mechanism of action for infliximab
in the setting of inflammatory bowel disease (IBD),
extrapolation to CD/UC cannot be recommended in the
absence of clinical studies in IBD—despite the absence of
direct evidence to support this notion [16, 17]. The impact of
different FccRIIIa polymorphisms has been evaluated
through genotyping CD patients. While these have been
linked to an increase in ADCC activity in in vitro assays, as
of yet no link to clinical outcome has been established [18,
19]. While ADCC may play a role in the therapeutic effect
of infliximab, many differences between different TNFa
inhibitors may underlie the observed differences in efficacy
in CD and UC, including dosing, half-life, TNFa-binding
affinity, Complement Dependent Cytotoxicity (CDC)
activity, and reverse signaling via transmembrane TNFa [20,
21]. Nevertheless, an influence of ADCC cannot be
excluded.
A copy of adalimumab ZRC-3197 (Exemptia) was
licensed as a biosimilar to Humira in India [22, 23].
Humira is not authorized in India, but Indian guidelines
allow a biosimilar product to be authorized if the reference
product is licensed and widely marketed for at least 4 years
in a country with a well established regulatory framework
[24]. The product was approved on the basis of compara-
tive physicochemical characterization and a comparative
clinical trial versus Humira including 120 RA patients (60
per arm) [25]. The trial lasted 12 weeks and was designed
as a superiority study rather than and equivalence or non-
inferiority study [25]. Based on the dossier, ZRC-3197 was
approved for RA, juvenile idiopathic arthritis, AS, psoriatic
arthritis, UC and CD, but interestingly not for the treatment
of psoriasis. The reason for not authorizing the product for
psoriasis is not clear.
3 Extrapolation of Immunogenicity Data
Possible differences in the sensitivity of different popula-
tions to mount an anti-drug antibody (ADA) response have
also been suggested as a reason to limit extrapolation of
immunogenicity findings [4]. While it is true that the
incidence of ADAs may differ in different indications—for
example, due to patient factors, the use of co-medication,
and dosing schedule—the relevance of this fact for
biosimilarity assessment may be questioned [26]. Both
clinical studies included in the dossier of CT-P13 reported
comparable incidences and magnitude in ADA formation
in studies including RA and AS patients, supporting the
notion that the two molecules do not differ in their
potential to elicit immune responses. In addition, higher
order structure determination based on ELISA using mul-
tiple antibodies showed that comparable epitopes were
recognized for CT-P13 and Remicade, suggesting the two
products are similarly recognized by various antibodies
[27]. Most importantly, antibodies against Remicade have
been found to cross react with CT-P13 in sera obtained
from IBD patients, independent of glycosylation of the
molecule [28]. Sera that were negative for Remicade were
also negative for CT-P13 [28]. Taken together, these data
do not suggest any concerns on extrapolating immuno-
genicity across indications.
When determining immunogenicity, the regulatory
objective is to compare the clinical impact of detected
ADA by correlation with suitably sensitive clinical end-
points [29, 30]. It has been argued that in order to gain full
insight into the longer-term outcomes, particularly the
immunogenicity profile of biosimilars, comparative clinical
data should be collected for more than 1 year—this last
point is reportedly particularly pertinent in the CD setting
for anti-TNF therapies [14]. However, most antibodies
against TNFa inhibitors are detected during the first year of
treatment, including in CD, so there is really no scientific
basis to support the need to collect data after 2 years [31–
33]. Even if antibodies were to develop after 1 year, there
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is no reason to expect that differences between a biosimilar
and its reference product will only become manifest after
this period. It is interesting that innovator products in most
cases have not been required to provide data beyond 1 year
in order to obtain marketing authorization. In the pivotal
52-week, double-blind maintenance study, M02-404, that
was used to support approval of Humira in CD, ADA
levels were not monitored at all [34]. ADA formation was
monitored for the maintenance of remission extension of
the induction study, which included week 4 responders
only, but there was an insufficient number of events to
assess impact of ADA on efficacy [34]. So, requiring
(comparative) immunogenicity data beyond 1 year lacks
scientific rationale, and would raise the bar for biosimilars
above that expected for innovator drugs, with obvious
negative consequences for the affordability of these
products.
4 Global Naming Practices
Once a biosimilar is approved, the medical community is
informed primarily through the approved labeling/pre-
scribing information of the product. The question then
arises about whether it is helpful to include any compara-
tive data from the biosimilarity exercise in the prescribing
information. Generic products fully copy the label of their
reference product, without including data on comparative
pharmacokinetic studies to demonstrate bioequivalence.
However, it has been suggested that the label of a
biosimilar should clearly state which aspects have been
studied and which aspects were granted based on extrap-
olation, while other commentators advocate identical labels
[35, 36]. Labeling requirements for biosimilars differ in
various regions, as discussed in the following sections.
4.1 EU
The EMA has issued guidance on the labeling that places
biosimilars in the same category as generics and hybrid
products: ‘‘The information from the reference medicinal
product’s Summary of Product Characteristics (SmPC) that
applies to the hybrid or biosimilar should be included in the
SmPC of the hybrid or biosimilar’’ [37]. Current EU
SmPCs do not differ between biosimilars and reference
products in terms of wording—although the brand name
has been replaced with the INN. The only relevant differ-
ence is that biosimilar SmPCs contain a black triangle,
indicating that the product is subject to additional post-
authorization monitoring by the EMA. Black triangles are
included in the SmPC for 5 years or until the EMA’s
Pharmacovigilance Risk Assessment Committee decides to
remove it from the list of medicines under additional
monitoring. There is one authorized biosimilar that has a
different SmPC from that of the reference product, namely
Binocrit. This reflects the historical regulatory context, in
which subcutaneous administration of the reference pro-
duct, Eprex, for treatment of renal anemia was tem-
porarily contraindicated because of increased incidence of
antibody-mediated pure red cell aplasia; this regulatory
action precluded comparative clinical studies of Binocrit
with Eprex in the preferred (‘most sensitive’) indication
to assess comparable safety and efficacy. This led to the
unique situation that, for epoetins, biosimilars initially did
not receive the same indications as the reference product.
While the SmPC does not provide information on the
comparative studies that were performed to demonstrate
biosimilarity, in the EU detailed information on the extent
of the data submitted by applicants can be found in Euro-
pean Public Assessment Reports (EPARs) [38]. The EPAR
summarizes the weight of evidence forming the basis of the
CHMP scientific opinion on the dossier. For a biosimilar
product, the EPAR identifies the scale of any detected
differences in physicochemical properties and discusses
how in vitro pharmacological and clinical data confirm the
biosimilar designation.
4.2 US
According to US legislation, biosimilars must utilize the
same mechanism or mechanisms of action for the condition
or conditions of use prescribed, recommended, or sug-
gested in the proposed labeling and are prescribed for
conditions that have been previously approved for the
reference product [39]. Furthermore, the route of admin-
istration, the dosage form, and the strength of the biosim-
ilar should be the same as those of the reference product.
Nevertheless, also in the US, it is possible to obtain a
license as a biosimilar for fewer than all indications for
which the reference product is licensed [40]. The pre-
scribing information of the first authorized biosimilar, fil-
grastim-sndz (Zarxio), is identical to its reference product
Neupogen with no reference to the studies performed
during the biosimilarity exercise.
In addition to the prescribing information, FDA shares
considerable data on the assessment of biosimilar products,
although some items are redacted that contain proprietary
or personal information. These documents, accessible via
Drugs@FDA [41], may contain more detailed information
than EPARs, encompassing chemistry, pharmacology, and
clinical data.
4.3 Other Regions
Other regions have chosen different approaches. Health
Canada has determined that biosimilars [in Canada named
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Subsequent Entry Biologics (SEBs)] will not be able to
utilize the Product Monograph (PM) of the reference bio-
logic drug in its entirety as that of its own products. This
may be explained in part by the fact that subsequent entry
biologics are authorized under the same legal pathway as
new biologics, unlike the EU and US where biosimilars
have a separate legal status [37]. The PM should state that
the product is a SEB. It should include key data on which
the decision for market authorization was made, including
tables showing the results of the comparisons between the
SEB and reference biologic drug and information on the
indications approved for use (Table 1). There should be no
claims for bioequivalence between the subsequent entry
biologics and the reference biologic drug nor should clin-
ical equivalence be claimed between the subsequent entry
biologic and the reference biologic drug [37]. This has
resulted in ‘hybrid’ labels that contain information both
from the innovator and of the biosimilars. Health Canada
also publishes a Summary of Basis of Decision for
approved drugs that provides more detailed information on
the Health Canada decision, but these are less detailed then
the published FDA review documents and EPARs [42]. A
similar approach has been taken in Australia where ‘‘rele-
vant clinical trial information generated on the reference
product and reported in the reference product PI may be
incorporated into the PI for the biosimilar. However these
data should be clearly identified as having been produced
using the reference product not the biosimilar’’ [43]. For
currently authorized biosimilars, this has resulted in pro-
duct labels including a detailed description of the (clinical)
comparability studies. Australia also shares more detailed
information on the assessment procedures in Australian
public assessment reports, which in content resemble
EPARs [44]. Both in Canada and Australia, the prescribing
information for generic medicinal products are identical to
their reference products. For India we were not able to find
regulatory assessment reports.
5 Discussion
Although the regulatory basis for extrapolation is com-
parable in all regulatory regions, regulatory agencies
weigh data differently in reaching conclusions about the
acceptability of extrapolation. The scientific rationale for
differing regulatory decisions regarding the extrapolation
of therapeutic indications for Remsima is not clear—
arguably, more weight was given by the Canadian
authority to uncertainty than to real evidence that differ-
ent mechanisms of action actually influence the clinical
efficacy of infliximab in the respective therapeutic indi-
cations. Regardless, the different decisions taken by reg-
ulatory agencies have led to calls to these agencies to
clarify the scientific basis for extrapolation of indications
[4, 5, 14].
The decision of various regulatory agencies to allow a
product on the market as a biosimilar, but with different
authorized indications, has given rise to considerable
confusion and raises some fundamental questions about
what it means to be a biosimilar. Since the inception of the
biosimilar regulatory framework, much effort has been
directed to emphasize that biosimilars are not generics.
While complexity of biologicals clearly justifies a tailored
regulatory route, the outcome of the biosimilarity exercise
should be a product that has demonstrated similarity to its
reference product, allowing a biosimilar product to refer to
the established efficacy and safety experience of the
innovator product. In our opinion this should be a binary
outcome; you either are, or you are not biosimilar to a
given reference product. Granting some indications but not
others is at odds with this concept. Of note, as has been
highlighted in a recently published article, also generic
medicinal products may not necessarily be identical to the
reference product in all respects [45]. Thus, the difference
in global regulatory practices applied to extrapolation of
indications and prescribing information for biosimilars
cannot be explained solely by ‘non-identicality’ of the
physicochemical properties of the drug product, but are
likely to be reflections of the different views of regulators
throughout the world in weighing evidence to support
biosimilarity.
EU guidance states that if relevant differences are
observed between a biosimilar and a reference product, it is
unlikely that biosimilarity will be established and a stand-
alone development to support a ‘full’ marketing autho-
rization should be considered instead [17, 37, 46]. Also, US
guidance states that if an observed difference is considered
clinically meaningful, this, in effect, precludes the product
from being considered biosimilar to its reference product
[47–49]. A recent opinion article written by Canadian
regulators notes, that:
‘‘The decision to extrapolate should be based pri-
marily on the demonstration of similarity through
extensive comparability studies that compare the
physicochemical attributes and the biological activity
between the biosimilar and reference product. Failure
to demonstrate that the intended biosimilar and the
reference product are highly similar at this stage
precludes extrapolation to indications and uses for
which the biosimilar mAb has not been studied. In
fact, if similarity cannot be sufficiently demonstrated
at this stage, sponsors should pursue a stand-alone
authorization pathway.’’ [17]
This raises some questions on the Canadian decision to
authorize CT-P13 as an SEB, rather than deciding that
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stand-alone development would be required to obtain
marketing authorization. The observed differences in reg-
ulatory decision making surrounding CT-P13 seems to
represent a difference in the approach to data interpreta-
tion, rather than a difference in the legislative basis of the
approval process. The content of the labels of biosimilars
throughout the world also reflect the dilemmas that regu-
lators are faced with: on the one hand, to authorize prod-
ucts that have demonstrated similarity to an existing
product but, on the other hand, also to inform physicians of
the data that was presented and upon which this decision is
based. Regulators need to strike a balance between pro-
viding the information without creating a situation that is
confusing to prescribers. Providing different labels for
biosimilars that have demonstrated comparability to an
existing reference product could strengthen a perception
that biosimilars are different from their reference product.
In addition, the basis of establishing biosimilarity is a
substantial database of comparative product quality data,
which may not be informative for HCPs and is also not
included in, for example, the Canadian label. The biosim-
ilarity exercise also includes a directly comparative eval-
uation of immunogenicity, often using bioanalytical
methods of higher sensitivity than those used to support the
authorization of the reference product—these data are also
not likely to be included in the prescribing information.
Physicians looking only at the label could conclude that the
evidence base is meager compared with the innovator drug,
thereby not acknowledging the different regulatory
approach of biosimilars. While there are many other
sources of information than the label (e.g., EPARs in the
EU and review documents published by the FDA), this
information may not be easily digestible for prescribers.
While recommended in most cases, randomized clinical
studies have limitations in detecting differences between
products that have been demonstrated to be structurally sim-
ilar by extensive analytical and in vitro pharmacological
characterization. Given their complexity and concerns for
immunogenicity, clinical trials are an important tool in con-
firming comparable clinical efficacy and establishing
Table 1 Biosimilar definitions and labeling practices in selected regulatory regions
Definition of biosimilar as defined in most current guidance Label structure: biosimilars vs innovator
EMA A biological medicinal product that contains a version of the
active substance of an already authorised original biological
medicinal product (reference medicinal product) in the EEA.
Similarity to the reference medicinal product in terms of quality
characteristics, biological activity, safety and efficacy based on a
comprehensive comparability exercise needs to [have been]
established [41]
Identical (the SmPCs of biosimilar products contain the addition
that the product is a biosimilar)
Health
Canada
[A subsequent entry biologic is] A biologic drug that enters the
market subsequent to a version previously authorized in Canada,
and with demonstrated similarity to a reference biologic drug.
An SEB relies in part on prior information regarding safety and
efficacy that is deemed relevant due to the demonstration of
similarity to the reference biologic drug [35]
Non-identical monographs, some information based on data
from reference product, other data from comparability studies
also included
FDA A biological product that is approved based on showing that it is
highly similar to an FDA-approved biological product, known as
a reference product, and has no clinically meaningful differences
in terms of safety and effectiveness from the reference product.
Only minor differences in clinically inactive components are
allowable in biosimilar products [42]
Identical
India A biological product/drug produced by genetic engineering
techniques and claimed to be ‘similar’ in terms of safety,
efficacy and quality to a reference biologic, which has been
granted a marketing authorization in India by DCGI on the basis
of a complete dossier, and with a history of safe use in India [24]
Hybrid label
Reference to biosimilarity studies (based on Exemptia label)
Australia A version of an already registered biological medicine that:
has a demonstrable similarity in physicochemical, biological
and immunological characteristics, efficacy, and safety, based on
comprehensive comparability studies
has been evaluated by the TGA according to this guideline and
other relevant EU guidelines adopted by the TGA [43]
Non-identical monographs, some information based on data
from reference product, other data from comparability studies
also included
DCGI Drug Controller General of India, EEA European Economic Area, SEB subsequent entry biologic, SmPC Summary of Product Charac-
teristics, TGA Therapeutic Goods Administration
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comparable immunogenicity profiles. However, clinical effi-
cacy data are not a prerequisite for being authorized as a
biosimilar. As experience with biosimilars is increasing, so is
the confidence in the ability to establish comparability using
analytical and in vitro methods. Currently, EU regulators are
contemplating prerequisites for waiving confirmatory clinical
efficacy studies for well characterisable products like G-CSF
(granulocyte-colony stimulating factor), which will bring the
biosimilarity exercise closer to the generic pathway [50].
6 Conclusions
The principles of establishing biosimilarity are to demonstrate
structural and functional similarity to a reference product
using the most discriminatory analytical methods. These data
are supported where necessary by focused clinical evaluation
using conditions that are adequately sensitive to evaluate real
risks that cannot be addressed solely by analytical data.
Allowing products on the market that do not have the same
authorized indications will create considerable confusion
about the concept of biosimilarity. The success of biosimilars
will depend on how they will be able to be interchanged with
the reference product andother biosimilars in clinical practice.
If multiple biosimilars are allowed on the market with dif-
ferent approved uses, this will create a complex situation that
will add hurdles for the successful uptake of biosimilars.
Despite the increasing number of countries that have
adopted biosimilar guidelines, there are clear differences in
local requirements in terms of weight of evidence and data
interpretation, labeling and naming of biosimilars. Such
divergent regulatory decisions on a key aspect of the
biosimilarity exercise like extrapolation do not help to
solve the confusion that exists at the level of healthcare
professionals and patients about biosimilars. Clearly there
is a need for global harmonization of the concept of
biosimilarity and regulatory requirements for biosimilars in
the various regulatory regions.
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